ClinicalTrials.gg
CompletedNCT02634489Updated Dec 18, 2015

EC905 Pharmacokinetic Profile Study

A Phase 1 interventional study of Tamsulosin HCl and Solifenacin Succinate in Phase 1, Healthy and Benign Prostatic Hyperplasia, sponsored by Astellas Pharma Europe B.V.. Completed at 1 site in Netherlands. Open to male participants aged 45 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-18.

Sponsored by Astellas Pharma Europe B.V. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.

Enrollment
35th of 48
46 · median 118
Started
2009
with 1 other
Phase 1
9 of 48
none open now
Registered
27th of 48
by date
Lead sponsor
3 of 48
Astellas Pharma Europe B.V.

Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 35th largest by enrollment, is one of 2 that started in 2009, is one of 9 in phase 1, and was the 27th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years to 80 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing tamsulosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

A study to compare the pharmacokinetics of tamsulosin HCl and solifenacin succinate after co-administration of single entity tablets and of the combination tablet EC905 under steady state conditions at three dose strengths.

Read the detailed description

There will be 3 dose cohorts of 15 subjects each. In Period 1, subjects will be randomized to either receive multiple doses of both tamsulosin HCl and solifenacin succinate as single entity tablets, or the combination tablet EC905. The alternate treatment will be provided in Period 2. The cohorts will be balanced for period effects and first-order carry over effects.

03

Conditions studied

  • Phase 1
  • Healthy
  • Benign Prostatic Hyperplasia
  • Lower Urinary Tract Symptoms

Keywords

  • Bladder outlet obstruction
  • Overactive bladder
  • Urinary incontinence
  • Omnic OCAS®
  • Vesicare®
  • Tamsulosin hydrochloride
  • Solifenacin succinate
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18.5 and 30.0 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to tamsulosin HCl, solifenacin succinate, EC905 or any of the components of the formulations used.
  • Any of the liver function tests above the at repeated measurements.
  • Any history of asthma, eczema, any other allergic condition or previous severe hypersensitivity to any other drug (excluding non-active hay fever).
  • Subject is at risk of urinary retention based on medical history.
  • A planned cataract surgery within 30 days after completion of the study.
  • Any clinically significant abnormality following the investigator's review of the pre-study physical examination, and clinical laboratory tests.
  • Abnormal pulse rate and/or blood pressure measurements at the pre-study visit as follows: pulse rate \<40 or >90 bpm; mean systolic blood pressure >160 mmHg; mean diastolic blood pressure >100 mmHg (blood pressure measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse will be measured automatically).
  • A marked baseline prolongation of /QTc interval after repeated measurements of 450 ms, a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS).
  • Use of any prescribed or OTC (over-the counter) drugs (including vitamins, natural and herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the Clinical Unit, except for occasional use of paracetamol (up to 3 g/day).
  • Regular use of any inducer of liver metabolism (e.g. barbiturates, rifampin) in the 3 months prior to admission to the Clinical Unit.
  • Any use of drugs of abuse within 3 months prior to admission to the Clinical Unit.
  • History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the Clinical Unit.
  • History of drinking more than 21 units of alcohol per week (1 unit = 270 cc of beer or 40 cc of spirits or 1 glass of wine) within 3 months prior to admission to the Clinical Unit.
  • Donation of blood or blood products within 3 months prior to admission to the Clinical Unit.
  • Positive serology test for , anti HAV (IgM), anti- or anti- 1+2.
  • Participation in any clinical study within 3 months or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study, provided that the clinical study did not entail a biological compound with a long terminal half-life. An exception is (partly) participation in Astellas study 905-CL-071, provided a of at least 12 days is considered prior to re-enrolment.
  • Employee of the Astellas Group or CRO involved in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Active comparator
    Tamsulosin HCl and Solifenacin Succinate

    Participants will receive daily doses of tamsulosin HCL and Solifenacin Succinate (3 dose strengths) as single tablets.

    Drug: Tamsulosin HCl · Drug: Solifenacin Succinate

  • Active comparator
    EC905 (tamsulosin HCI and solifenacin succinate)

    Participants will receive a fixed combination tablet (3 dose strengths).

    Drug: EC905

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of tamsulosin HCl and solifenacin succinate in plasma: AUCtau

    AUCtau: area under the concentration - time curve (AUC) during the time interval between consecutive dosing

    Time frame: Day 12

  2. PK of tamsulosin HCl and solifenacin succinate in plasma: Cmax

    Cmax: maximum concentration

    Time frame: Day 12

Secondary outcomes

  1. Safety profile assessed by adverse events, physical examination and vital signs, routine safety laboratory tests, and 12-lead ECG

    Vital signs include blood pressure, pulse rate. Safety laboratory test includes urinalysis, hematology, and biochemistry. ECG: Electrocardiogram

    Time frame: Day 0 up to and including the post study visit (the PSV is scheduled between 7 to 14 days after (early) discharge on study day 13)

  2. PK profile Ctrough

    Ctrough: Trough concentration

    Time frame: Day 10, 11, 12, 13

  3. PK profile PTR

    PTR: Peak Trough Ratio

    Time frame: Day 12

  4. PK profile Tmax

    Tmax: Time to attain Cmax

    Time frame: Day 12

07

Study locations

1 site
  • Site NL1
    Zuidlaren, Drente 9471 GP, Netherlands
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2015
First posted
Dec 18, 2015
Start
Mar 2009
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Last update
Dec 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02634489
Responsible party
Sponsor
First posted
Dec 18, 2015
Start date
Mar 2009
Primary completion
Jul 2009
Completion
Jul 2009
Last update
Dec 18, 2015

Study contacts

Director Medical Sciences
study director · Astellas Pharma Europe B.V.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tamsulosin · Solifenacin · EC905

Start the discussion